Q² Solutions strengthens scalable, next generation sequencing approaches with Illumina’s NovaSeq™ X Plus platform solution, enhancing data quality and analysis capabilities with sustainable operations

Expanding on deep expertise with industry-leading solutions to meet the unique sequencing needs of sponsors

Focused on tackling complex customer challenges with purposeful innovation, Q² Solutions recently announced the incorporation of Illumina’s NovaSeq™ X Plus sequencing system at its state-of-the-art laboratory facility —Innovation Laboratories— in Research Triangle Park, NC. In late March 2023, Q² Solutions was the first delivery of the NovaSeq X Plus in North Carolina. As part of a broader effort to effectively address the evolving needs of clinical studies, the addition of NovaSeq X Plus leads the next phase in the evolution of precision medicine with improved efficiency and capacity to gain insight into the human genome. Whether interrogating the transcriptome, exome or whole genome, integration of NovaSeq X Plus will enable efficient and comprehensive characterization leading to new genomic discoveries with the potential to impact patient care.

With more than 13 years of experience with Illumina sequencing technologies, our scientific team at Q² Solutions provides:

• Expertise and capabilities to support large-scale biologically complex studies.
• Robust and reproducible sequencing workflows with industry leading quality control processes.
• Customer-focused scientific leadership for custom assay development and bioinformatic solutions.

Q² Solutions is committed to reducing our impact to the environment through sustainable laboratory practices. Illumina’s system helps minimize the environmental impact of sequencing operations with a 90 percent reduction in packaging waste for reagents and a 50 percent reduction in plastic mass.

“It is important to know that the innovations we develop or technologies we integrate into our genomic interrogation portfolio do not have to be complicated to provide exceptional data quality at the scale needed for each customer,” said Pat Hurban, vice president and general manager, Genomics Laboratories, Q² Solutions. “NovaSeq X Plus is an integral component of our larger commitment to answer the evolving needs of precision medicine. Looking ahead, we will continue to prioritize the integration of additional transformative offerings across our global laboratory network allowing our expert teams to help our sponsors advance science and critical drug development with efficiency, innovation, and a continued commitment to quality.

About Q² Solutions

Q² Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository and specimen management, and clinical trial sample and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We focus our innovative solutions and scientific expertise on ADME, bioanalytical, genomics, immunoassays testing, vaccines and central laboratory services, including flow cytometry, anatomic pathology, molecular and companion diagnostics, and decentralized clinical trials while providing meticulous regional and global clinical trial implementation support and high-quality data delivery. Our Translational Science and Innovation Laboratory (TSAIL) provides access to a broad range of resources, including a multidisciplinary approach to early-stage human biomarker discovery and clinical sample testing to help accelerate drug development.

At Q² Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need.

Click here to learn more about our genomics capabilities.